SCHEMBL1384940

SCHEMBL1384940

Cc1ccc(-c2c(-c3ccncc3)c(-c3ccc(F)cc3)nc3[nH]ncc23)o1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
MAPK14 Q16539 16/20 0.39
CSNK1D P48730 4/20 0.39
MAPK11 Q15759 4/20 0.38
MAPK13 O15264 3/20 0.38
MAPK12 P53778 3/20 0.38
GCGR P47871 2/20 0.38
CSNK1A1 P48729 1/20 0.38
CSNK1E P49674 1/20 0.38
MAPK9 P45984 1/20 0.37
MAPK10 P53779 1/20 0.37
ADORA3 P0DMS8 2/20 0.37
ADORA2A P29274 2/20 0.37
ADORA2B P29275 2/20 0.37
ADORA1 P30542 2/20 0.37
EGFR P00533 1/20 0.37
RAF1 P04049 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1386461 0.87 MAPK14 (0.53) MAPK14CSNK1DMAPK11MAPK13MAPK12
SCHEMBL2931861 0.85 MAPK14 (0.48) MAPK14CSNK1DMAPK11MAPK13MAPK12
SCHEMBL29652689 0.85 MAPK14 (0.48) MAPK14CSNK1DMAPK11MAPK13MAPK12
SCHEMBL1386922 0.82 ADORA1 (0.46) KDM4EALDH1A1MAPTMAPK14CSNK1D
SCHEMBL1386446 0.80 MAPK14 (0.49) KDM4EALDH1A1MAPTMAPK1MAPK14
SCHEMBL1386287 0.78 MAPK14 (0.46) KDM4EALDH1A1MAPTMAPK1MAPK14
SCHEMBL2930581 0.77 POLB (0.46) MAPK14CSNK1DMAPK11MAPK13MAPK12
SCHEMBL2929925 0.76 MAPK14 (0.40) MAPK14CSNK1DMAPK11MAPK13MAPK12
SCHEMBL1384646 0.76 MAPK14 (0.40) MAPK1MAPK14CSNK1DMAPK11MAPK13
SCHEMBL2929750 0.75 MAPK14 (0.40) MAPK14CSNK1DMAPK11MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
JP-4814783-B2 2011-11-16 JP claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
EP-1611131-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach y Compagnia S.A. (ES) 2006-01-04 EP claimed
WO-2004076450-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach Y Compañia S.A. (ES) 2004-09-10 WO claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 KDM4E 3384/4885ALDH1A1 789/4885MAPT 1383/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 KDM4E 3953/4885ALDH1A1 1040/4885MAPT 2290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.